Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01505439
Other study ID # VENUS-MUI
Secondary ID
Status Completed
Phase Phase 4
First received January 4, 2012
Last updated June 13, 2016
Start date June 2011
Est. completion date June 2014

Study information

Verified date June 2016
Source Korea University Anam Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study is to investigate the effects of solifenacin on urgency urinary incontinence symptoms and incontinence quality-of-life (I-QoL) in female patients with clinically significant stress urinary incontinence accompanied by urgency urinary incontinence.


Recruitment information / eligibility

Status Completed
Enrollment 311
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients are selected from those who meets one of criteria

- Patients with a positive cough provocation test

- Based on 3-day voiding diary, patients with:

- Urinary frequency (eight or more micturitions per day or 24 hours)

- Urinary urgency (two or more episodes per day or 24 hours)

- Urge incontinence (three or more episodes for 3 days)

Exclusion Criteria:

- Breast-feeding women or females of childbearing potential with the intention to become pregnant during the study

- Post-void residual urine volume (PRV) of 150 cc or more

- Patients who experienced acute ureteral obstruction requiring an indwelling catheter

- Patients who experienced clinically significant pelvic organ prolapse or lower urinary tract surgery within 6 months prior to the initiation of the present study

- Patients who underwent a urinary incontinence operation within 1 year

- Any condition that, in the opinion of the investigator, is a contraindication for anticholinergic treatment, including severe narrow-angled glaucoma, urinary retention, gastric retention, severe myasthenia, severe hepatic insufficiency or severe ulcerative colitis

- Significant hepatic or renal disease, defined as having greater than twice the upper limit of the reference ranges for serum concentrations of aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase or creatinine

- Patients who have any of neurological disorders such as stroke, multiple sclerosis, spinal cord injury, and Parkinson's disease

- Patients who use an indwelling catheter or practice intermittent self-catheterization

- Recurrent UTIs defined as having been treated for symptomatic UTIs 3 times or more in the last year

- Symptomatic acute urinary tract infection (UTI) during the run-in period

- Patients who received any of the following prohibited concomitant drugs within 14 days prior to randomization: Treatment performed within the 14 days preceding randomization, or expected to initiate treatment during the study with:

- Any anticholinergics other than the trial drug

- Any drug treatment for overactive bladder. Estrogen treatment started more than 2 months prior to inclusion is allowed

- Patients taking an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study

- Patients with chronic constipation or history of severe constipation

- Treatment with any of potent CYP3A4 inhibitors, such as cyclosporine, vinblastine, macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin) or antifungal agents (e.g. ketoconazole, itraconazole, micronazole)

- Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study initiation and not agreeing to use such methods during the entire study period and for at least 1 month thereafter. Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives, surgical procedures (tubal ligation or vasectomy), or continence

- Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
solifenacin
oral

Locations

Country Name City State
Korea, Republic of Site KR00001 Chonam
Korea, Republic of Site KR00002 Chungnam
Korea, Republic of Site KR00003 Daegu
Korea, Republic of SIte KR00004 Incheon
Korea, Republic of Site KR00005 Pusan
Korea, Republic of Site KR00006 Seoul

Sponsors (2)

Lead Sponsor Collaborator
Jeong Gu Lee Astellas Pharma Korea, Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12 Baseline and week 12 No
Secondary Percent change in the mean number of urge urinary incontinence episodes per 24 hours Baseline, week 4 and week 12 No
Secondary Change in the mean number of urge urinary incontinence episodes per 24 hours urgency episodes: defined as those with a Bladder Sensation Scale rating of = 3 in the voiding diary Baseline, week 4 and week 12 No
Secondary Change in the mean frequency of urination per 24 hours Baseline, week 4 and week 12 No
Secondary Percent change in the mean frequency of urination Baseline, week 4 and week 12 No
Secondary Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours Baseline, week 4 and week 12 No
Secondary Change in the mean number of severe urgency episodes per 24 hours severe urgency episodes: defined as those with a Bladder Sensation Scale rating of = 4 in the voiding diary Baseline, week 4 and week 12 No
Secondary Changes in overactive bladder symptom score (OABSS) questionnaire Change in total and each of OABSS items Baseline, week 4 and week 12 No
Secondary Changes in short urogenital distress inventory (UDI-6) Change in total and each UDI-6 items Baseline, week 4 and week 12 No
Secondary Changes in short incontinence impact questionnaire (IIQ-7) Change in total and each of IIQ-7 items Baseline, week 4 and week 12 No
Secondary Safety assessed by the incidence and severity of side effects For 12 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Completed NCT01770691 - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence N/A
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1